Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform
April 15, 2021 10:55 ET
|
Biosplice Therapeutics, Inc.
New investors include Eventide, aMoon, SymBiosis II, Sands Capital and VeritionProceeds to support Biosplice’s clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its...
Darrin M. Beaupre, M.D., Ph.D. joins Samumed as Chief Medical Officer, Oncology
December 01, 2020 10:00 ET
|
Samumed, LLC.
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, a clinical-stage biotechnology company pioneering therapeutics based on RNA alternative splicing for major diseases, announced today that...
Michael White, Ph.D. joins Samumed as Chief Scientific Officer
June 01, 2020 11:00 ET
|
Samumed, LLC.
SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, a clinical-stage biotechnology company pioneering Wnt Pathway therapeutics for major diseases, announced today that Dr. Michael White will...
Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis
May 22, 2020 09:00 ET
|
Samumed, LLC.
SAN DIEGO, May 22, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of results from the Phase 2a trial of lorecivivint, an investigational CLK/DYRK1A inhibitor that modulates...